ECR 2019 / C-1042
The enhancement pattern of arterial phase on MRI potentially predicts pancreatic neuroendocrine tumours with somatostatin receptor-2 expression
Keywords:
Abdomen, Oncology, Pancreas, MR, MR-Diffusion/Perfusion, MR-Functional imaging, Contrast agent-intravenous, Outcomes analysis, Surgery, Cancer, Pathology
Authors:
Y. Hu; Shanghai/CN
DOI:
10.26044/ecr2019/C-1042
References
- de Herder W W.
When and How to Use Somatostatin Analogues[J].
Endocrinology and Metabolism Clinics of North America,
2018,47(3):549-555.
- Werner R A,
Ilhan H,
Lehner S,
et al.
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy[J].
Molecular Imaging and Biology,
2018.
- Cives M,
Strosberg J R.
Gastroenteropancreatic Neuroendocrine Tumors[J].
CA Cancer J Clin,
2018,68(6):471-487.
- Carmona-Bayonas A,
Jiménez-Fonseca P,
Custodio A,
et al.
Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors[J].
Current Oncology Reports,
2017,19(11).
- Crabtree J S.
Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy[J].
Frontiers in Endocrinology,
2017,8.
- Dromain C,
Déandréis D,
Scoazec J Y,
et al.
Imaging of neuroendocrine tumors of the pancreas[J].
Diagnostic and Interventional Imaging,
2016,97(12):1241-1257.
- Garcia-Carbonero R,
Sorbye H,
Baudin E,
et al.
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J].
Neuroendocrinology,
2016,103(2):186-194.
- Rai U,
Thrimawithana T R,
Valery C,
et al.
Therapeutic uses of somatostatin and its analogues: Current view and potential applications[J].
Pharmacol Ther,
2015,152:98-110.
- Sun L,
Coy D H.
Somatostatin and its Analogs[J].
Curr Drug Targets,
2016,17(5):529-537.